BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Woopen C, Schleußner K, Akgün K, Ziemssen T. Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis. Front Immunol 2021;12:701752. [PMID: 34234787 DOI: 10.3389/fimmu.2021.701752] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
Number Citing Articles
1 Bellucci G, Rinaldi V, Buscarinu MC, Reniè R, Bigi R, Pellicciari G, Morena E, Romano C, Marrone A, Mechelli R, Salvetti M, Ristori G. Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started? Front Immunol 2021;12:755333. [PMID: 34646278 DOI: 10.3389/fimmu.2021.755333] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Azimzadeh M, Möhn N, Ghane Ezabadi S, Moghimi Esfandabadi Z, Soleimani A, Ranjbar E, Jahromi M, Seyedebrahimi R, Skripuletz T, Moharrami Kasmaie F. The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic. Biomolecules 2021;11:1372. [PMID: 34572585 DOI: 10.3390/biom11091372] [Reference Citation Analysis]
3 Okan G, Vural P. Worsening of the vitiligo following the second dose of the BNT162B2 mRNA COVID-19 vaccine. Dermatol Ther 2021;:e15280. [PMID: 34931408 DOI: 10.1111/dth.15280] [Reference Citation Analysis]
4 Cohen JA, Bermel RA, Grossman CI, Hersh CM, Hyland M, Mowry EM, Naismith R, Naylor ML, Nicholas J, Rajbhandar R, Singh CM, Tintorè M, Zabalza A, Ziemssen T, Williams JR, Montalban X. Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions. Mult Scler 2022;:13524585211061343. [PMID: 34994577 DOI: 10.1177/13524585211061343] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Kantarcioglu B, Iqbal O, Lewis J, Carter CA, Singh M, Lievano F, Ligocki M, Jeske W, Adiguzel C, Gerotziafas GT, Fareed J. An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations. Clin Appl Thromb Hemost 2022;28:107602962110566. [DOI: 10.1177/10760296211056648] [Reference Citation Analysis]